Beta-blockers have been a cornerstone of post-MI management for over four decades, primarily based on evidence from clinical trials conducted in the 1970s and 1980s, which demonstrated a survival benefit in a broad cohort of infarction patients. However, revolutionary advances in acute coronary care—including rapid reperfusion strategies, robust antithrombotic regimens, and optimized secondary prevention—have profoundly altered the risk profile and clinical course of these patients. Consequently, it became imperative to reassess the therapeutic value of beta-blockers in the current era, especially in patients exhibiting preserved cardiac contractility.

The meta-analysis integrated datasets from the REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, and CAPITAL-RCT trials conducted across diverse geographic regions including Spain, Italy, Sweden, Norway, Denmark, and Japan. This multinational collaboration facilitated a granular and robust evaluation of beta-blocker efficacy by encompassing variations in patient demographics, beta-blocker types, and treatment protocols. Approximately half of the participants received beta-blockers, while the other half did not, allowing for head-to-head comparison over an average follow-up approaching four years. The incidence of major cardiovascular events—a composite endpoint of all-cause mortality, recurrent MI, or heart failure hospitalization—was statistically indistinguishable between treatment arms.

Dr. Borja Ibáñez, CNIC Scientific Director and principal investigator, emphasized that subgroup analyses failed to reveal any differential benefit across age, sex, or beta-blocker subclass. Intriguingly, prior signals from the REBOOT trial hinted at potential harm in female patients receiving beta-blockers post-MI, a concern the meta-analysis sought to clarify. While women showed a trend toward increased adverse events under beta-blocker therapy, this observation did not reach statistical significance, underscoring the need for ongoing evaluation of sex-specific treatment responses in cardiovascular medicine.

Importantly, the study delineates the clinical context where beta-blockers retain their indispensable role. Patients with reduced LVEF (<50%) post-MI, as well as those with chronic heart failure or arrhythmias, continue to derive clear mortality and morbidity reduction from beta-blocker therapy. The trials analyzed intentionally excluded patients already on beta-blockers for these indications, ensuring the findings apply strictly to initiating beta-blocker therapy in infarction survivors with normal ejection fraction. This distinction is critical in guiding personalized treatment algorithms and avoiding unnecessary medication burden.

The implications of these findings are profound given that approximately 70% of contemporary MI survivors now present with preserved cardiac function—an epidemiological shift attributed to improved acute management and secondary prevention. This paradigm shift fundamentally questions the universal prescription of beta-blockers, urging a tailored approach based on cardiac function assessment. Dr. Valentín Fuster, General Director at CNIC and a global authority on cardiovascular medicine, remarked that this meta-analysis conclusively overturns treatment dogma that has remained largely unquestioned for more than 40 years, heralding a new standard of care that could substantially refine patient management worldwide.

In practical terms, this evolution reduces exposure to potential beta-blocker-associated side effects, including fatigue and sexual dysfunction, thereby improving long-term quality of life for millions of patients. The investigators caution against abrupt discontinuation of beta-blockers without clinical consultation, as the decision must consider individual patient indications beyond MI treatment. Physicians are encouraged to assess beta-blocker necessity during routine follow-ups and discontinue therapy judiciously in patients with preserved ejection fraction who lack alternate indications.

This meta-analysis also exemplifies the power of international scientific collaboration executed at unprecedented speed, enabling rapid synthesis of high-quality evidence to resolve contentious clinical questions. By harmonizing raw data across heterogeneous trials, the researchers achieved unparalleled statistical power and confidence in their conclusions. Such methodological rigor and collaboration serve as a model for future cardiovascular research, particularly in precision medicine initiatives targeting nuanced patient subgroups.

Furthermore, the CNIC’s commitment to investigating sex-based differences in cardiovascular treatment outcomes highlights an essential dimension of patient-centered care, seeking to optimize therapeutic efficacy and safety across diverse populations. This focus aligns with contemporary emphasis on equity and inclusiveness in clinical trials and guideline formulation.

As the clinical community digest this pivotal evidence, it is anticipated that international guidelines will be updated to reflect the limited role of beta-blockers in post-MI patients with preserved ventricular function. This transition heralds a more rational, evidence-based prescription approach, minimizing unnecessary pharmacotherapy while safeguarding patients with established indications.

In summary, this meta-analysis represents a milestone in cardiovascular therapeutics, conclusively demonstrating that beta-blockers do not reduce mortality, recurrent myocardial infarction, or heart failure in infarction survivors with normal cardiac function. The clinical narrative evolves toward stratified medicine, reserving beta-blocker therapy for patients with impaired ejection fraction or other validated indications. This paradigm shift will transform clinical practice globally, improving patient outcomes and quality of life while fostering more efficient resource utilization.

Subject of Research: People

Article Title: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction

News Publication Date: 9-Nov-2025

Web References: http://dx.doi.org/10.1056/NEJMoa2512686

Image Credits: CNIC

Keywords: Health and medicine, Human health, Medical specialties, Pharmacology, Pharmaceuticals, Epidemiology, Diseases and disorders, Clinical medicine

For over 40 years, beta blockers have been routinely prescribed to patients post-myocardial infarction to reduce mortality risks through their mechanisms of lowering heart rate, oxygen demand, and preventing arrhythmias. However, advancements in reperfusion therapies and standard care have transformed the clinical landscape, necessitating a reassessment of the benefits attributed to these drugs within a modern therapeutic context. The REBOOT Trial rigorously evaluated the impact of discontinuing beta blockers in patients with normal left ventricular function, a subgroup that had not been extensively studied under contemporary treatment protocols.

The trial enrolled 8,505 patients across 109 hospitals in Spain and Italy, randomly assigning participants to either continue or cease beta blocker treatment after discharge. All patients otherwise received state-of-the-art care, including prompt coronary artery reperfusion and modern pharmacotherapies. Over a median follow-up period of almost four years, the primary endpoints—rates of death, recurrent myocardial infarction, and hospitalization for heart failure—showed no statistically significant difference between the beta blocker and non-beta blocker groups. These results strongly suggest that beta blockers may no longer confer the protective benefits once assumed in this patient population.

A particularly illuminating aspect of the REBOOT substudy was its gender-specific analysis, which revealed concerning findings for female patients. Women treated with beta blockers exhibited a 2.7 percent higher absolute risk of adverse outcomes—including death, subsequent heart attacks, and heart failure hospitalization—compared to untreated women with preserved cardiac function. Conversely, men receiving beta blockers did not experience this increased risk. This sex-specific distinction underscores the importance of personalized medicine and calls for further exploration into the molecular and physiological mechanisms underlying these differences.

Scientific understanding posits that beta blockers improve outcomes primarily by reducing cardiac workload and suppressing arrhythmogenic risk immediately after myocardial injury. Yet, contemporary treatment approaches emphasize rapid restoration of coronary artery patency through percutaneous interventions, effectively minimizing ischemic damage. This evolution leads to less residual myocardial impairment and may diminish the therapeutic necessity of beta blockers, especially in patients without reduced left ventricular ejection fraction. The thorough design of REBOOT reflects this hypothesis, aiming to update clinical practices based on robust evidence rather than tradition.

Dr. Borja Ibáñez, the trial’s principal investigator and CNIC Scientific Director, emphasizes the transformative potential of the findings. Highlighting that currently over 80 percent of patients with uncomplicated myocardial infarction are prescribed beta blockers at discharge, he suggests these results will prompt significant revisions in international guidelines. The implications extend beyond clinical efficacy to patient quality of life, considering beta blockers’ known side effects such as fatigue, bradycardia, and sexual dysfunction. Streamlining post-infarct medication regimens could enhance adherence and reduce needless exposure to drug-related adverse events.

The REBOOT Trial joins an influential cohort of cardiovascular studies spearheaded by CNIC and Mount Sinai institutions, each shifting paradigms in heart disease management. Previous landmark trials include the SECURE study, which demonstrated that a polypill combining aspirin, ramipril, and atorvastatin significantly lowers cardiovascular events, and the DapaTAVI trial, which showed benefits of sodium-glucose cotransporter 2 inhibitors in patients undergoing transcatheter aortic valve implantation. Together, these studies illustrate a profound evolution in understanding and optimizing cardiovascular care with precision medicine.

From a methodological standpoint, the REBOOT Trial’s randomized controlled design, extensive sample size, and multicenter collaboration provide a robust framework for drawing conclusive evidence. The absence of pharmaceutical industry funding further strengthens the trial’s credibility, ensuring findings are free of commercial bias. The integration of sophisticated subgroup analyses enriches insights into patient stratification, particularly regarding sex differences and cardiac function parameters, a level of granularity uncommon in large-scale cardiovascular trials.

The trial’s findings echo an emerging trend in contemporary cardiology that questions the indiscriminate continuation of historical treatments without reassessing their roles amid advances in therapeutic intervention and diagnostics. Modern reperfusion therapy has substantially mitigated the extent and consequence of myocardial injury, thus recalibrating the risk-benefit analysis of adjunctive medications. In this light, beta blockers appear less vital for patients with preserved ventricular function, whereas their use may remain justified in those with impaired cardiac output.

Another critical consideration arising from REBOOT is the enhanced understanding of sex-specific responses to cardiovascular medications. The data indicating elevated adverse outcomes in women prescribed beta blockers prompts a re-evaluation of gender inclusivity in clinical trials and therapeutic approaches. Differentiation in drug metabolism, hormonal influences, and genetic determinants may all contribute to this phenomenon, signaling a broader imperative for tailored, individualized treatment algorithms.

The clinical community awaits further analyses and guideline updates to incorporate these findings into routine practice. Meanwhile, the results invite clinicians to critically appraise the necessity of beta blockers in patients after uncomplicated myocardial infarction, especially those whose cardiac function remains robust. This nuanced approach could refine risk stratification and therapeutic decision-making, ultimately improving patient outcomes and quality of life.

In summary, the REBOOT Trial represents a seismic shift in cardiology, overturning a four-decade-old dogma around beta blocker use post-myocardial infarction with preserved ejection fraction. The study exemplifies the critical need for ongoing appraisal of legacy treatments under the lens of contemporary evidence and underscores the dynamic nature of medical practice guided by rigorous scientific inquiry. As cardiac care continues to evolve, these insights pave the way towards more effective, personalized, and patient-centered medicine.

Subject of Research: People

Article Title: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction

News Publication Date: 30-Aug-2025

Image Credits: Mount Sinai Health System

Keywords: Cardiovascular disorders, Clinical trials, Drug studies, Medical treatments, Drug delivery, Drug therapy